What’s behind Trump’s drug pricing proposal? This insight explores key policy tools, global scenarios, and long-term ...

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés ...

OECD countries formally use QALYs in pricing and reimbursement decisions. See how HTA practices differ and where policies ...

Spending Review: £29bn for NHS. OHE’s Graham Cookson calls for clarity on productivity and investment in prevention for ...

Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually and impose economic costs exceeding $150 billion by 2050.

New OHE insight on immunisation: despite high returns on investment, global spending lags. We outline why and how countries ...

This is the first in a series of OHE Insights on the history, implications and possible impact of President Trump’s Executive Order on a “Most Favoured Nation” (MFN) pricing model for pharmaceuticals.

Join us for an online CERSI-PGx Health Economics Workshop on 10 June 2025, from 13:00–17:00 BST, with experts from NHS England, NICE, the University of Manchester, and Bangor University. CERSI-PGx is ...

Neil McAuslane PhD, MSc, BSc. Scientific Director of the Centre for Innovation in Regulatory Science (CIRS) overseeing the scientific content of both CIRS regulatory and HTA programmes. Key research ...

The UK is confronting a seismic demographic shift with an ageing population and declining fertility rates. In preparing for this change, it is critical that we shift how we think about health across ...